olfactory receptor family 6 subfamily R member 2 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR6R2P profile across patient tissues and cancer cell-line models. OR6R2P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, OR6R2P is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, OR6R2P RNA expression shows 6,741 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, THCA, and STAD as cancer lineages where OR6R2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR6R2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR6R2P survival associations across molecular data types. OR6R2P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR6R2P RNA expression–survival associations across cancer types. High OR6R2P expression shows unfavorable associations in KICH, CHOL, KIRC, THCA, LUSC and ACC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for OR6R2P RNA expression.
This table summarizes OR6R2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR6R2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR6R2P shows lower tumor expression in THCA, LUAD, BRCA and LUSC and higher tumor expression in UCEC and HNSC. The THCA box plot shows higher OR6R2P RNA expression in normal versus tumor tissue (log2 FC = −0.132, t-test p = .003).
This table shows molecular features associated with OR6R2P in patient tissues and cancer cell lines. In patient samples, OR6R2P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
